

**CLAIMS**

1. A DNA transfer vector containing a sequence coding for a p185<sup>neu</sup>-fragment, wherein said sequence is selected from the group consisting of SEQ  
5 ID N. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14.
2. A DNA transfer vector according to claim 1, which is a plasmid.
3. The plasmid of claim 2, further containing a transcription promotor.
4. The plasmid of claim 3, wherein the promotor is CMV.
5. The plasmid of claim 2, further containing 4 CpG motifs.
- 10 6. The plasmid of claim 5, further containing 8 CpG motifs.
7. Pharmaceutical composition containing a DNA transfer vector according to any one of claims 1-6 in admixture with pharmaceutically acceptable vehicles and excipients.
8. The composition according to claim 7, which is suitable for parenteral  
15 administration.
9. The composition of claim 8, which is in the form of injectable solution.
10. A combined pharmaceutical preparation containing at least two different plasmids according to claims 1-6, for simultaneous, sequential or separate therapeutic use.
- 20 11. A combined preparation according to claim 10, which is in a form suitable for DNA vaccination.
12. Use of a plasmid according to claims 1-6 to prepare a pharmaceutical composition for use in the preventive or therapeutical treatment of subjects at risk of developing p185<sup>neu</sup> positive tumours, or of patients having primary  
25 tumours, metastasis or relapses of p185<sup>neu</sup>-expressing tumours.
13. The use according to claim 12, for the preparation of a DNA vaccine.